2026-01-04
Researchers from Takeda Pharmaceutical Company and CiRA, as part of the Takeda-CiRA Joint Program (T-CiRA), led by Associate Professor Akitsu Hotta (Department of Clinical Application, CiRA), have developed a novel approach of genome editing to repair muscle stem (satellite) cells, offering new hope for Duchenne muscular dystrophy (DMD) treatment.
2025-12-26
